||5R00CA218694-04 Interpret this number
||University Of Utah
||Blood Metabolite Profiles and Risk of Developing Endometrial Cancer
Cancer is a leading cause of death in the United States, with a third of diagnoses attributed to modifiable risk
factors including obesity and poor diet. Understanding the role of these risk factors in cancer development is
crucial for the provision of appropriate public health guidance for cancer prevention.
Breast cancer remains the highest incidence cancer among women in the United States, and incidence rates
for endometrial cancer are projected to dramatically increase over the next decade. Epidemiological, clinical
and laboratory evidence suggests that diet may be relevant for breast and endometrial cancer prevention,
although the evidence base lacks consistency, perhaps owing to imprecise dietary measures, and a failure to
account for associations that may vary by tumor subtype. Furthermore, endometrial cancer is especially
obesity-driven, but the underlying mechanisms have yet to be fully characterized.
There is a need for better objective measures of diet, including dietary biomarkers, that can be used to improve
dietary assessment. Metabolomics is a novel and emerging technology in molecular epidemiology that can be
used to measure hundreds to thousands of circulating metabolites simultaneously, more than 200 of which
have been recently linked to an individual’s diet and/or adiposity. Furthermore, metabolomics can be used to
highlight biological mechanisms of interest in relation to disease. This novel technology is advancing rapidly,
and much work is yet to be done in applying it in an epidemiologic context.
To address this unmet need, I propose to apply metabolomics to understanding the relationships of diet and
adiposity with female cancers. I will first quantify the relationship between circulating metabolites and habitually
consumed foods in a feeding study with a gold-standard measure of diet (weighed food) among
postmenopausal women in order to develop objective dietary biomarkers. Such work is critical for correct
interpretation of any diet-related metabolite signals that may be observed in subsequent cancer studies. Next, I
will measure the association between pre-diagnostic circulating diet-related metabolites and estrogen receptor-
negative (ER-) breast cancer using nested case-control data from three prospective cohorts. ER- breast cancer
is rare, aggressive and understudied. Consequently, the etiology is poorly understood, including potential
dietary risk factors. Finally, I will determine whether pre-diagnostic circulating metabolites are associated with
incident endometrial cancer, and their relation to diet or adiposity using nested case-control data from four
prospective cohorts. No studies have explored metabolite signatures of endometrial cancer and their relation to
adiposity and diet using data from US-based prospective studies. These studies may uncover unknown
metabolic pathways involved in the etiology of breast and endometrial cancer that may also be applicable to
other obesity-driven cancers, and identify key pathways for developing and evaluating targeted cancer
Dissemination and analysis of the quality assurance (QA) and quality control (QC) practices of LC-MS based untargeted metabolomics practitioners.
, O'Donovan C.
, Playdon M.
, Beecher C.
, Beger R.D.
, Bowden J.A.
, Broadhurst D.
, Clish C.B.
, Dasari S.
, Dunn W.B.
, et al.
Metabolomics : Official journal of the Metabolomic Society, 2020-10-12; 16(10), p. 113.
One-carbon metabolites, B vitamins and associations with systemic inflammation and angiogenesis biomarkers among colorectal cancer patients: results from the ColoCare Study.
, Holowatyj A.N.
, Gigic B.
, Brezina S.
, Geijsen A.J.M.R.
, Ose J.
, Lin T.
, Hardikar S.
, Himbert C.
, Warby C.A.
, et al.
The British journal of nutrition, 2020-05-28; 123(10), p. 1187-1200.
Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease.
, Maschek J.A.
, Cox J.E.
, Hauner B.J.
, Hopkins P.N.
, Hunt S.C.
, Holland W.L.
, Summers S.A.
, Playdon M.C.
The Journal of clinical investigation, 2020-03-02; 130(3), p. 1363-1376.